Morgan Stanley Increases Unum Therapeutics (UMRX) Price Target to $21.00
Unum Therapeutics (NASDAQ:UMRX) had its price objective hoisted by research analysts at Morgan Stanley from $20.00 to $21.00 in a research report issued on Thursday, Stock Target Advisor reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 116.27% from the company’s previous close.
UMRX has been the topic of several other reports. Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Unum Therapeutics in a research note on Tuesday, September 18th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research note on Monday, September 17th.
Shares of UMRX stock opened at $9.71 on Thursday. Unum Therapeutics has a 1 year low of $9.01 and a 1 year high of $17.66.
In other news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $12.47, for a total transaction of $143,217.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Several institutional investors have recently added to or reduced their stakes in UMRX. Citadel Advisors LLC acquired a new position in shares of Unum Therapeutics during the 1st quarter worth about $416,000. Platinum Investment Management Ltd. bought a new stake in shares of Unum Therapeutics during the 1st quarter worth about $2,499,000. Point72 Asset Management L.P. bought a new stake in shares of Unum Therapeutics during the 1st quarter worth about $3,599,000. Highland Capital Management LP bought a new stake in shares of Unum Therapeutics during the 1st quarter worth about $770,000. Finally, Millennium Management LLC bought a new stake in shares of Unum Therapeutics during the 1st quarter worth about $982,000. Institutional investors own 51.50% of the company’s stock.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Featured Article: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.